Clinical Trials Browser

Interventional × Neoplasms × ensartinib × Clear all

NCT01625234 2021-10-06

Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer

Phase 1/2 Completed

Carcinoma, Non-Small-Cell Lung, Neoplasms